Science Publications

Sign Up
Sign In
Submit
Current Research in Public Health
Cite This Article Share Download PDF XML
  1. Home
  2. Journals
  3. Current Research in Public Health
  4. Archive
  5. Volume 1, Issue 1, 2021
  6. Article
Systematic Review Open Access November 29, 2021

Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review

Ishita Gupta 1,* and Ekta Subhash Chand Sharma 2
1
Infectious Disease Unit, Dubai Health Authority, Dubai, UAE
2
Department of Anesthesia, Dubai Health Authority, Dubai, UAE
Publihed in: Current Research in Public Health (Volume 1, Issue 1, 2021)
Page(s): 81-90
DOI: 10.31586/gjeid.2021.179
Received
October 28, 2021
Revised
November 25, 2021
Accepted
November 28, 2021
Published
November 29, 2021
Keywords
Mucormycosis; Candida; COVID-19; Pneumonia; Systematic Review
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright: Copyright © The Author(s), 2021. Published by Scientific Publications
Article metrics
Views
556
Downloads
211

Cite This Article

APA Style
Gupta, I. , & Sharma, E. S. C. (2021). Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review. Current Research in Public Health, 1(1), 81-90. https://doi.org/10.31586/gjeid.2021.179
ACS Style
Gupta, I. ; Sharma, E. S. C. Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review. Current Research in Public Health 2021 1(1), 81-90. https://doi.org/10.31586/gjeid.2021.179
Chicago/Turabian Style
Gupta, Ishita, and Ekta Subhash Chand Sharma. 2021. "Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review". Current Research in Public Health 1, no. 1: 81-90. https://doi.org/10.31586/gjeid.2021.179
AMA Style
Gupta I, Sharma ESC. Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review. Current Research in Public Health. 2021; 1(1):81-90. https://doi.org/10.31586/gjeid.2021.179 
@Article{crph179,
AUTHOR = {Gupta, Ishita and Sharma, Ekta Subhash Chand},
TITLE = {Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review},
JOURNAL = {Current Research in Public Health},
VOLUME = {1},
YEAR = {2021},
NUMBER = {1},
PAGES = {81-90},
URL = {/10.31586/gjeid-1-1-610.31586/gjeid/1/1/6},
ISSN = {2831-5162},
DOI = {10.31586/gjeid.2021.179},
ABSTRACT = {Introduction: The city of Wuhan in China reported the first case of coronavirus, termed as SARS-CoV-2, in December 2019. To date, 187,827,660 cases have been reported to the WHO (3). With current research focusing on potential therapeutic agents for the coronavirus disease and vaccines, there remain major gaps in our understanding of the pathophysiology and clinical course of this viral pneumonia. Secondary infections are one of them. In this systematic review, we analyze the outcomes of two fungal infections in patients of COVID-19, viz. Mucormycosis and candida. Methodology: A systematic review has been done on secondary infections with mucor and candida fungi in patients of COVID-19. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used. Twenty-three studies were included in the final analysis. Our review included studies from various countries across the globe. The risk of bias was analyzed using the NIH Quality Assessment Tool for Case Series Studies. This study did not require ethical approval as data was obtained from already available databases, and patients were not directly involved. Results: A total of 23 articles were included in the final review and the total number of patients included was 79 Male: female ratio was calculated to be 1.6 and the average age of patients was 52 years (ranging from 24-86 years). Various types of comorbidities were seen in the included patients, the most common being diabetes mellitus. Among the 18 patients in the cohort of mucormycosis, 7 patients died and four studies did not report patient outcomes. Among the 61 patients, 13 patients died and one patient was still ventilated at the time of publication. Conclusion: Secondary infections after COVID-19 are a cause of major concerns. Further studies and case reports are needed to better understand the various other types of secondary infections and also to formulate strategies to prevent these.},
}
%0 Journal Article
%A Gupta, Ishita
%A Sharma, Ekta Subhash Chand
%D 2021
%J Current Research in Public Health

%@ 2831-5162
%V 1
%N 1
%P 81-90

%T Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review
%M doi:10.31586/gjeid.2021.179
%U /10.31586/gjeid-1-1-610.31586/gjeid/1/1/6

TY  - JOUR
AU  - Gupta, Ishita
AU  - Sharma, Ekta Subhash Chand
TI  - Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review
T2  - Current Research in Public Health
PY  - 2021
VL  - 1
IS  - 1
SN  - 2831-5162
SP  - 81
EP  - 90
UR  - /10.31586/gjeid-1-1-610.31586/gjeid/1/1/6
AB  - Introduction: The city of Wuhan in China reported the first case of coronavirus, termed as SARS-CoV-2, in December 2019. To date, 187,827,660 cases have been reported to the WHO (3). With current research focusing on potential therapeutic agents for the coronavirus disease and vaccines, there remain major gaps in our understanding of the pathophysiology and clinical course of this viral pneumonia. Secondary infections are one of them. In this systematic review, we analyze the outcomes of two fungal infections in patients of COVID-19, viz. Mucormycosis and candida. Methodology: A systematic review has been done on secondary infections with mucor and candida fungi in patients of COVID-19. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used. Twenty-three studies were included in the final analysis. Our review included studies from various countries across the globe. The risk of bias was analyzed using the NIH Quality Assessment Tool for Case Series Studies. This study did not require ethical approval as data was obtained from already available databases, and patients were not directly involved. Results: A total of 23 articles were included in the final review and the total number of patients included was 79 Male: female ratio was calculated to be 1.6 and the average age of patients was 52 years (ranging from 24-86 years). Various types of comorbidities were seen in the included patients, the most common being diabetes mellitus. Among the 18 patients in the cohort of mucormycosis, 7 patients died and four studies did not report patient outcomes. Among the 61 patients, 13 patients died and one patient was still ventilated at the time of publication. Conclusion: Secondary infections after COVID-19 are a cause of major concerns. Further studies and case reports are needed to better understand the various other types of secondary infections and also to formulate strategies to prevent these.
DO  - Mucormycosis and Candida Infections in Patients of COVID-19 Pneumonia: A Systematic Review
TI  - 10.31586/gjeid.2021.179
ER  -